Discovery and development of gliflozins/ja: Difference between revisions
Discovery and development of gliflozins/ja
Created page with "'''表3：'''チアゾール環の関わり方によるIC<sub>50</sub>値の違い（他の構造は何も変えていない（X = Cl, R = フェニルと2-フリル）。 {| class="wikitable" |- ! 化合物 !! IC<sub>50</sub> (nM) |- |align="center"| File:Mynd fyrir toflu3-1.png ||align="center"| 0.720 |- |align="center"| File:Mynd fyrir toflu3-2.png ||align="center"| 1.11 |}" Tags: Mobile edit Mobile web edit |
Created page with "Gliflozins " Tags: Mobile edit Mobile web edit |
||
| Line 119: | Line 119: | ||
|} | |} | ||
== こちらも参照 == | |||
* [[Sodium-glucose transport proteins/ja]] | |||
* [[Sodium-glucose transport proteins]] | * [[SLC5A2/ja]] | ||
* [[SLC5A2]] | * [[SGLT1/ja]] | ||
* [[SGLT1]] | * [[SGLT2/ja]] | ||
* [[SGLT2]] | * [[Dapagliflozin/ja]] | ||
* [[Dapagliflozin]] | * [[Empagliflozin/ja]] | ||
* [[Empagliflozin]] | * [[Canagliflozin/ja]] | ||
* [[Canagliflozin]] | * [[Ipragliflozin/ja]] | ||
* [[Ipragliflozin]] | |||
{{Drug design/ja}} | |||
{{Drug design}} | |||
[[Category:Drug discovery|Gliflozins]] | [[Category:Drug discovery|Gliflozins]] | ||
[[Category:SGLT2 inhibitors| ]] | [[Category:SGLT2 inhibitors| ]] | ||
